JP2024105296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024105296A5 JP2024105296A5 JP2024066707A JP2024066707A JP2024105296A5 JP 2024105296 A5 JP2024105296 A5 JP 2024105296A5 JP 2024066707 A JP2024066707 A JP 2024066707A JP 2024066707 A JP2024066707 A JP 2024066707A JP 2024105296 A5 JP2024105296 A5 JP 2024105296A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- cancer
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 54
- 102000025171 antigen binding proteins Human genes 0.000 claims 27
- 108091000831 antigen binding proteins Proteins 0.000 claims 27
- 210000004027 cell Anatomy 0.000 claims 16
- 238000006467 substitution reaction Methods 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 108091008874 T cell receptors Proteins 0.000 claims 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 230000002068 genetic effect Effects 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 102220516971 Core-binding factor subunit beta_I54F_mutation Human genes 0.000 claims 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 2
- 108010075704 HLA-A Antigens Proteins 0.000 claims 2
- 101001005720 Homo sapiens Melanoma-associated antigen 4 Proteins 0.000 claims 2
- 101001005723 Homo sapiens Melanoma-associated antigen 8 Proteins 0.000 claims 2
- 102100025077 Melanoma-associated antigen 4 Human genes 0.000 claims 2
- 102100025076 Melanoma-associated antigen 8 Human genes 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003236 esophagogastric junction Anatomy 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 102200095678 rs11004439 Human genes 0.000 claims 1
- 102200078978 rs121907888 Human genes 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882131P | 2019-08-02 | 2019-08-02 | |
| DE102019121007.0 | 2019-08-02 | ||
| DE102019121007.0A DE102019121007A1 (de) | 2019-08-02 | 2019-08-02 | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US62/882,131 | 2019-08-02 | ||
| US201962905782P | 2019-09-25 | 2019-09-25 | |
| US62/905,782 | 2019-09-25 | ||
| JP2022506617A JP7476298B2 (ja) | 2019-08-02 | 2020-07-31 | Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質 |
| PCT/EP2020/071660 WO2021023658A1 (en) | 2019-08-02 | 2020-07-31 | Antigen binding proteins specifically binding mage-a |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506617A Division JP7476298B2 (ja) | 2019-08-02 | 2020-07-31 | Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024105296A JP2024105296A (ja) | 2024-08-06 |
| JP2024105296A5 true JP2024105296A5 (https=) | 2025-03-04 |
Family
ID=74165587
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506617A Active JP7476298B2 (ja) | 2019-08-02 | 2020-07-31 | Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質 |
| JP2024066707A Pending JP2024105296A (ja) | 2019-08-02 | 2024-04-17 | Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506617A Active JP7476298B2 (ja) | 2019-08-02 | 2020-07-31 | Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US11840577B2 (https=) |
| EP (1) | EP4007776A1 (https=) |
| JP (2) | JP7476298B2 (https=) |
| KR (1) | KR20220041161A (https=) |
| CN (2) | CN115925958A (https=) |
| AR (1) | AR120585A1 (https=) |
| AU (1) | AU2020324515A1 (https=) |
| BR (1) | BR112022001923A2 (https=) |
| CA (1) | CA3148937A1 (https=) |
| CL (2) | CL2022000252A1 (https=) |
| CO (1) | CO2022002044A2 (https=) |
| CR (1) | CR20220086A (https=) |
| DE (1) | DE102019121007A1 (https=) |
| IL (1) | IL290268A (https=) |
| MX (3) | MX2022001422A (https=) |
| PE (1) | PE20221021A1 (https=) |
| PH (1) | PH12022550230A1 (https=) |
| TW (1) | TWI878330B (https=) |
| WO (1) | WO2021023658A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3428194T (lt) | 2017-07-14 | 2021-12-10 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| TW202229327A (zh) * | 2020-10-02 | 2022-08-01 | 美國衛生與公眾服務部 | 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體 |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| MX2023010541A (es) | 2021-03-09 | 2023-11-24 | Cdr Life Ag | Proteinas de union al antigeno del peptido del mhc mage-a4. |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| IL308258A (en) * | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| EP4091627A1 (en) | 2021-05-21 | 2022-11-23 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for magea4-derived epitopes |
| WO2023099606A1 (en) | 2021-12-01 | 2023-06-08 | Immunocore Limited | Treatment of mage-a4 positive cancer |
| EP4472742A1 (en) * | 2022-02-03 | 2024-12-11 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| CN114457002B (zh) * | 2022-02-23 | 2023-08-22 | 中山大学 | 一种分离细胞外囊泡亚群的方法及其应用 |
| WO2023215183A1 (en) * | 2022-05-02 | 2023-11-09 | Tscan Therapeutics, Inc. | Multiplexed t cell receptor compositions, combination therapies, and uses thereof |
| EP4534554A1 (en) * | 2022-06-01 | 2025-04-09 | Corregene Biotechnology Co., Ltd. | Mage-a1 specific tcr and use thereof |
| JP2025525382A (ja) * | 2022-06-24 | 2025-08-05 | アムジエン・インコーポレーテツド | Ｍａｇｅａ４特異的ｔ細胞受容体 |
| WO2024035962A2 (en) * | 2022-08-12 | 2024-02-15 | Ingenious Targeting Laboratories | Genetically modified non-human having humanized gamma and delta tcr variable genes |
| CA3264474A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT |
| AU2024214482A1 (en) | 2023-02-03 | 2025-08-07 | Zelluna Immunotherapy As | Anti-mage-a4 t cell receptors |
| CN116519936B (zh) * | 2023-02-28 | 2025-11-07 | 杭州凯保罗生物科技有限公司 | 用于前列腺癌早期检测的肿瘤自身抗原/抗体组合及应用 |
| CN121358777A (zh) | 2023-07-27 | 2026-01-16 | 伊玛提克斯生物技术有限公司 | 抗mageb2的抗原结合蛋白 |
| WO2025233432A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide |
| WO2025233431A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| WO2026008886A1 (en) | 2024-07-05 | 2026-01-08 | Immatics Biotechnologies Gmbh | Means and methods for the quantification of target expression |
| WO2026025031A1 (en) | 2024-07-26 | 2026-01-29 | Modernatx, Inc. | Mrna encoding mageb2 tcer molecule |
| WO2026078231A1 (en) | 2024-10-11 | 2026-04-16 | T-Therapeutics Limited | Soluble non-aggregating immune ligand |
| WO2026082746A1 (en) | 2024-10-14 | 2026-04-23 | Immatics Biotechnologies Gmbh | Bispecific molecule formulation |
| CN119529098B (zh) * | 2025-01-22 | 2025-05-30 | 北京可瑞生物科技有限公司 | 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4179338A (en) | 1977-09-19 | 1979-12-18 | Gordon Maurice R | Microbiological medium suitable for sterilization by ionizing radiation |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ES2233974T3 (es) | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana. |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| CA2243235C (en) | 1996-01-17 | 2010-08-10 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| MXPA02005559A (es) | 1999-12-06 | 2004-09-10 | Univ Illinois | Proteinas de tcr de alta afinidad y metodos. |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| PT1558643E (pt) | 2002-11-09 | 2009-08-24 | Immunocore Ltd | Apresentação de um receptor das células t |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| WO2005076009A2 (en) | 2004-01-28 | 2005-08-18 | Immatics Biotechnologies Gmbh | Method for identifying and quantifying of tumour-associated peptides |
| US9963510B2 (en) * | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| JP5276846B2 (ja) | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
| WO2008053573A1 (fr) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remède pour néoplasme malin |
| MX338397B (es) | 2007-08-29 | 2016-04-15 | Sanofi Aventis | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
| KR101680906B1 (ko) | 2007-09-26 | 2016-11-30 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| EP2337795A2 (en) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| US9840695B2 (en) | 2009-04-28 | 2017-12-12 | Agriculture Victoria Services Pty Ltd | Plant technology |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| EP2486049A1 (en) | 2009-10-06 | 2012-08-15 | The Board Of Trustees Of The UniversityOf Illinois | Human single-chain t cell receptors |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| HRP20171164T1 (hr) | 2010-09-20 | 2017-10-20 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t stanični receptori i t stanični epitopi |
| TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| AU2012302778B2 (en) | 2011-08-31 | 2016-11-24 | Mie University | Vaccine preparation for cancer treatment |
| WO2013048243A1 (en) * | 2011-09-29 | 2013-04-04 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
| WO2013057596A1 (en) | 2011-10-21 | 2013-04-25 | Atena Srl | Anatomic cushion accumulator for thermal treatment with heat or cold |
| EP2660250B1 (en) | 2012-05-02 | 2018-11-14 | Deutsches Rheuma-Forschungszentrum Berlin | Tcr transgenic mouse model for immune disease |
| KR102499753B1 (ko) | 2012-07-27 | 2023-02-16 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | Ｔ 세포 수용체 조작 |
| KR102480188B1 (ko) * | 2012-09-14 | 2022-12-21 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| SMT202100464T1 (it) | 2013-03-14 | 2021-11-12 | Macrogenics Inc | Molecole bispecifiche che sono immunoreattive con cellule effettrici immunitarie che esprimono un recettore di attivazione |
| US11634502B2 (en) | 2013-03-15 | 2023-04-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
| AU2014301777B2 (en) | 2013-06-26 | 2017-03-30 | Xlifesc, Ltd. | High-stability T-cell receptor and preparation method and application thereof |
| US11203783B2 (en) | 2013-11-21 | 2021-12-21 | Repertoire Genesis Incorporation | T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis |
| IL263466B2 (en) | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| US10202640B2 (en) | 2014-05-07 | 2019-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing |
| EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| CN120988137A (zh) | 2015-01-23 | 2025-11-21 | 赛诺菲 | 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体 |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| EP3095792A1 (en) | 2015-05-19 | 2016-11-23 | Klinikum rechts der Isar der Technischen Universität München | T cell receptor with specificity for myeloperoxidase peptide and uses thereof |
| MX2018004721A (es) | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| GB201522592D0 (en) | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| GB201604492D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| CN116731156A (zh) | 2016-03-16 | 2023-09-12 | 伊玛提克斯生物技术有限公司 | 用于癌症免疫治疗的转染t细胞和t细胞受体 |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018026018A1 (ja) | 2016-08-05 | 2018-02-08 | 国立大学法人東北大学 | Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断 |
| GB201617716D0 (en) | 2016-10-19 | 2016-11-30 | Ucl Business Plc | Cell |
| GB201617714D0 (en) | 2016-10-19 | 2016-11-30 | Ucl Business Plc | T Cell receptor |
| DE102016121899A1 (de) | 2016-11-15 | 2018-05-17 | Immatics Biotechnologies Gmbh | Verfahren zur Herstellung von elektrokompetenten Hefezellen und Verfahren zur Verwendung dieser Zellen |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| WO2018226931A1 (en) * | 2017-06-07 | 2018-12-13 | David Weiner | Mage-a vaccines and methods of treatment using the same |
| LT3428194T (lt) | 2017-07-14 | 2021-12-10 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| DE102018100967B4 (de) | 2018-01-17 | 2019-08-14 | Immatics US, Inc. | Verfahren zur feststellung der wirksamkeit von viralen vektoren |
| EP3747456A4 (en) | 2018-01-31 | 2021-12-01 | Tohoku University | PROCESS FOR REGULATING THE EXPRESSION OF THE SPECIFIC MHC OF AN ANTIGEN |
| BR112020016176A2 (pt) | 2018-02-09 | 2022-02-22 | Immatics Us Inc | Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| KR20210010896A (ko) | 2018-05-14 | 2021-01-28 | 이뮤노코어 리미티드 | 이기능성 결합 폴리펩타이드 |
| CA3102254A1 (en) | 2018-06-04 | 2019-12-12 | Apo-T B.V. | Methods and means for attracting immune effector cells to tumor cells |
| GB201819540D0 (en) | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| AU2020209991B2 (en) | 2019-01-17 | 2024-11-14 | Immunocore Limited | Formulations |
| GB201901306D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| CN118994397A (zh) | 2019-05-21 | 2024-11-22 | 诺华股份有限公司 | 针对bcma的三特异性结合分子及其用途 |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| GB201911286D0 (en) | 2019-08-07 | 2019-09-18 | Ucl Business Plc | Method |
| CN114729305A (zh) | 2019-10-17 | 2022-07-08 | 苏州丹罗医药有限公司 | 用于免疫治疗的嵌合抗原受体、制备方法及其应用 |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
-
2019
- 2019-08-02 DE DE102019121007.0A patent/DE102019121007A1/de active Pending
-
2020
- 2020-07-30 US US16/943,779 patent/US11840577B2/en active Active
- 2020-07-31 AU AU2020324515A patent/AU2020324515A1/en active Pending
- 2020-07-31 KR KR1020227006480A patent/KR20220041161A/ko active Pending
- 2020-07-31 CN CN202210924728.8A patent/CN115925958A/zh active Pending
- 2020-07-31 CR CR20220086A patent/CR20220086A/es unknown
- 2020-07-31 WO PCT/EP2020/071660 patent/WO2021023658A1/en not_active Ceased
- 2020-07-31 TW TW109125935A patent/TWI878330B/zh active
- 2020-07-31 EP EP20751505.7A patent/EP4007776A1/en active Pending
- 2020-07-31 CN CN202080055666.0A patent/CN114616244A/zh active Pending
- 2020-07-31 BR BR112022001923A patent/BR112022001923A2/pt unknown
- 2020-07-31 JP JP2022506617A patent/JP7476298B2/ja active Active
- 2020-07-31 PE PE2022000179A patent/PE20221021A1/es unknown
- 2020-07-31 MX MX2022001422A patent/MX2022001422A/es unknown
- 2020-07-31 PH PH1/2022/550230A patent/PH12022550230A1/en unknown
- 2020-07-31 CA CA3148937A patent/CA3148937A1/en active Pending
- 2020-11-27 AR ARP200103306A patent/AR120585A1/es unknown
-
2022
- 2022-01-31 CL CL2022000252A patent/CL2022000252A1/es unknown
- 2022-01-31 IL IL290268A patent/IL290268A/en unknown
- 2022-02-01 MX MX2022011411A patent/MX2022011411A/es unknown
- 2022-02-01 MX MX2022011410A patent/MX2022011410A/es unknown
- 2022-02-25 CO CONC2022/0002044A patent/CO2022002044A2/es unknown
-
2023
- 2023-02-27 CL CL2023000562A patent/CL2023000562A1/es unknown
- 2023-10-09 US US18/483,174 patent/US20240052054A1/en not_active Abandoned
- 2023-12-13 US US18/538,242 patent/US12269881B2/en active Active
-
2024
- 2024-04-17 JP JP2024066707A patent/JP2024105296A/ja active Pending
-
2025
- 2025-02-11 US US19/050,553 patent/US20250215084A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024105296A5 (https=) | ||
| JP7724332B2 (ja) | クローディン１８．２結合部分およびその利用 | |
| JP2020512019A5 (https=) | ||
| KR20220064986A (ko) | 항-pd-l1 단일-도메인 항체 및 그의 유도체 및 용도 | |
| HRP20220131T1 (hr) | Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste | |
| JP2020500523A5 (https=) | ||
| CN119161491A (zh) | 双特异性重组蛋白及其应用 | |
| JP2018521008A (ja) | 腫瘍形成を処置するための治療用組成物および治療方法 | |
| CN114616337A (zh) | 嵌合CD3融合蛋白与基于anti-CD3的双特异性T细胞激活元件的联合表达 | |
| JP7809635B2 (ja) | Ｌａｇ－３アンタゴニスト治療のための定量的空間プロファイリング | |
| US20250179173A1 (en) | Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor | |
| JP2021531819A (ja) | 低ａｄｃｃ／ｃｄｃ機能性モノクローナル抗体、及びその調製方法と使用 | |
| US20220332818A1 (en) | Bispecific antibody targeting pd-1 and tim-3 | |
| JP2023504149A (ja) | Ｃｄ３００ｃ抗原またはその受容体に特異的に結合するキメラ抗原受容体 | |
| IL297104A (en) | Antibodies to NKP46 and their constructs for the treatment of cancer and infections | |
| CN117603360A (zh) | 用于治疗癌症的多特异性抗体 | |
| CA3168743A1 (en) | Methods of treating cancer by administering a pd-1 inhibitor | |
| Mehrotra et al. | Immunotherapy guided precision medicine in solid tumors | |
| WO2009147695A1 (ja) | 抗がん剤 | |
| US20230277666A1 (en) | Chimeric antigen receptor comprising co-stimulatory receptor and application thereof | |
| CN116355099A (zh) | 重组抗人ox40和pd-l1双特异抗体及应用 | |
| WO2026042803A1 (ja) | がん治療におけるプラチナ系薬剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 | |
| WO2026012487A1 (zh) | 靶向bcma和gprc5d的双特异性car-t细胞 | |
| JP2020507338A (ja) | 癌糖ペプチドに対するモノクローナルおよびヒト化抗体 | |
| WO2025238157A1 (en) | Multispecific binding agent suitable for use in cancer immune therapy |